Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Exon 21 L858R Mutation”

19 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 19 results

Large-scale testing (Phase 3)Not Yet RecruitingNCT06970782
What this trial is testing

Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 278
Early research (Phase 1)Ended earlyNCT04862780
What this trial is testing

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Who this might be right for
Lung NeoplasmsCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+21 more
Blueprint Medicines Corporation 177
Testing effectiveness (Phase 2)UnknownNCT01955421
What this trial is testing

Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc

Who this might be right for
Advanced Stage Non Small Cell Lung Cancer
Sun Yat-sen University 224
Early research (Phase 1)Looking for participantsNCT06955988
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc. 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT05256290
What this trial is testing

Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations

Who this might be right for
Non-Small Cell Lung CancerAdvanced Non-Small Cell Squamous Lung CancerMetastatic Lung Non-Small Cell Carcinoma+7 more
Black Diamond Therapeutics, Inc. 200
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07709585
What this trial is testing

Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients

Who this might be right for
Advanced Non-small Cell Lung Cancer (NSCLC)EGFR Exon 19 Deletion MutationEGFR Exon 21 Mutation+1 more
Guangzhou University of Traditional Chinese Medicine 124
Testing effectiveness (Phase 2)Study completedNCT05263947
What this trial is testing

Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation

Who this might be right for
Carcinoma, Non-Small-Cell LungBevacizumabTyrosine Kinase Inhibitor+1 more
Tianjin Medical University Cancer Institute and Hospital 35
Early research (Phase 1)Not Yet RecruitingNCT07461727
What this trial is testing

An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases

Who this might be right for
Non-Small Cell Lung CancerMetastatic Non-small Cell Lung CancerLiver Metastases+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 15
Not applicableLooking for participantsNCT06053099
What this trial is testing

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

Who this might be right for
Non Small Cell Lung CancerEGFR Activating MutationEGFR DEL19+1 more
Intergroupe Francophone de Cancerologie Thoracique 300
Testing effectiveness (Phase 2)Looking for participantsNCT06574347
What this trial is testing

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 120
Testing effectiveness (Phase 2)Looking for participantsNCT07624487
What this trial is testing

Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma

Who this might be right for
Lung Adenocarcinoma Metastatic
Taipei Medical University Hospital 50
Testing effectiveness (Phase 2)Ended earlyNCT04908956
What this trial is testing

Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO)

Who this might be right for
NSCLC Stage IVEGFR Gene Mutation
ETOP IBCSG Partners Foundation 6
Post-approval studies (Phase 4)Study completedNCT02514174
What this trial is testing

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

Who this might be right for
Carcinoma, Non-Small-Cell LungErbB Receptors
Boehringer Ingelheim 25
Testing effectiveness (Phase 2)Ended earlyNCT04099836
What this trial is testing

Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

Who this might be right for
Non Small Cell Lung Cancer
Duke University 7
Testing effectiveness (Phase 2)UnknownNCT04988607
What this trial is testing

Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC

Who this might be right for
Lung Cancer
Guangdong Association of Clinical Trials 90
Early research (Phase 1)Ended earlyNCT05153408
What this trial is testing

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Who this might be right for
Lung NeoplasmCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+24 more
Blueprint Medicines Corporation 20
Testing effectiveness (Phase 2)Looking for participantsNCT07505173
What this trial is testing

Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer

Who this might be right for
Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases
Tianjin Medical University Cancer Institute and Hospital 74
Large-scale testing (Phase 3)Active Not RecruitingNCT05338970
What this trial is testing

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Who this might be right for
Nonsquamous Non-small Cell Lung CancerEGFR L858REGFR Exon 19 Deletion
Daiichi Sankyo 586
Post-approval studies (Phase 4)Ended earlyNCT02695290
What this trial is testing

Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)

Who this might be right for
Carcinoma, Non-Small-Cell LungErbB Receptors
Boehringer Ingelheim 1